Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2015

View Archived Issues

Genentech's LGR5-targeting ADC inhibits growth of colon cancer

SMRX-11: A clot-specific streptokinase

Novel CSF-1R inhibitor shows promising results for bone tumors

Italian and U.S. academic team patents ASAH1 inhibitors

AbbVie patents V1bR ligands

Chengdu Bestchiralbio announces DPP IV inhibitors

Roche reports anti-HBV agents

Eisai presents splicing factor 3B modulators

Calitor Sciences and Sunshine Lake Pharma present PI3K inhibitors

European Comission approves Horizon's Ravicti

Managed access program for ixazomib begins for patients with multiple myeloma

Heptares enters strategic drug discovery collaboration with Pfizer

Vericiguat holds promise for heart failure

Applications seeking approval of Stelara for Crohn's disease submitted by Janssen

Dose expansion implemented in study of immunomodulator EF-022 in patients with solid tumors

Phase I study of Intercept's INT-767 begins

FDA approves Empliciti for previously treated multiple myeloma

Novel kinase inhibitor shows promise for the treatment of HCC

Valneva releases data from phase II study of prophylactic C. difficile vaccine candidate

Phase III results for MD-1003 in MS patients with chronic visual loss following optic neuritis

Almirall to acquire dermatology specialist Poli Group

Puma Biotechnology reports plans for neratinib MAA filing

Roche licenses Proximagen VAP-1 inhibitor for inflammatory disease

Baxalta's Adynovate launched for the treatment of hemophilia in adult patients

Mallinckrodt closes sale of CMDS business to Guerbet

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...